Study Review – Prostate-specific antigen response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes

This review brings you reports of new developments which summarises sub-analysis data from the ARASENS trial as well as a post hoc analysis.

Independent commentary for the review has been provided by Professor Anthony Joshua, a medical oncologist at the Kinghorn Cancer Centre and the Garvan Institute of Medical Research and conjoint Professor at UNSW Sydney.

Please login below to download this issue (PDF)

Subscribe